Valuation Where do you think the business will be in 3, 5 or 10 years time? Either privatisation to clean the books and get the ship running with less leakages.Read more

Duopharma Biotech Bhd (KLSE: DPHARMA, ticker 7148) Healthcare – Pharmaceuticals / Biotech Investment Review Recommendation: HOLD (Initiated) Key Metrics Company Overview Duopharma Biotech Bhd is a leading pharmaceutical manufacturer in Malaysia, involved in the research, development, manufacturing, and distribution of generic and specialty pharmaceutical products. Its operations span: Ethical Classic : General therapeutic generics (e.g., cardiovascular, anti-infectives) Ethical Specialty : Bio-similars for oncology, renal, and metabolic diseases Consumer Healthcare (CHC) : Notable OTC brands like Champs, Flavettes, and Uphamol As of 2025, it exports to multiple countries and operates from 3 GMP-certified manufacturing facilities.Read more

Yoong Onn sells everyday home and lifestyle items, and some investors see today’s low market mood as a chance to buy a steady Malaysian retailer at a cheaper price than it may deserve. The appeal comes from its mix of retail and distribution, a habit of paying dividends, and signs the share price may be settling after a long slide—though weaker consumer spending and rising costs could still bite.Read more

Infoline Tec sells the behind-the-scenes tech that keeps networks and data centres running, but its recent results hint that growth is slowing even as it stays cash-rich and debt-free. With a share buy-back plan, a new university tie-up, and questions around future sales and thinner profit margins, this is a story of solid foundations facing a tougher next chapter.Read more

Poh Kong sells jewelry and gold products across Malaysia, and its business tends to hold up when people look for a safer place to park their money. The stock price looks low compared with its recent profits, but the company’s reliance on Malaysian shoppers and an uneven dividend record are key things to watch.Read more

Naim Holdings looks overlooked after a sharp share price slide, even though it’s still making money, generating cash, and sitting on more cash than debt. The key question is whether its project-driven results can stay steady enough for contract wins, asset moves, or a dividend return to change how investors view the business.Read more